H&T Presspart has announced its acquisition of global rights to a capsule-based dry powder inhaler developed by Hovione. H&T Presspart will manufacture and commercialize the DPI, which will be marketed as PowdAir Plus. According to the announcement, the two companies will continue to collaborate.
The PowdAir Plus DPI, which was designed with the needs of developing markets in mind, contains only four components, made entirely of plastic, which makes the inhaler economical and easy to use, the company says. Any dry powder formulation can be filled into size 3 capsules for use with the device.
H&T Presspart Chairman Peter Schmelzer commented, “This is a strategically significant partnership for H&T Presspart and underlines our commitment to forging alliances that accelerate the development, global scale-up and commercialization of novel drug delivery solutions for respiratory patients. This partnership supports our strategy to respond to the rapidly growing demand for dry powder inhalers across a range of needs, with this collaboration focused on providing a solution for developing markets.”
Hovione Technology CEO Peter Villax said, “We are delighted with the collaboration with H&T Presspart. With our expertise in DPI invention, design and development and Presspart’s mastery of large scale industrialization and global distribution, we are very confident about success.”
